ConCallIQ
Go Pro
Home › Cohance Lifesciences › Revenue History

Cohance Lifesciences Revenue History — Quarter by Quarter

Cohance Lifesciences's revenue moved from ₹549 Cr in Q1 FY26 to ₹619 Cr in Q4 FY26, a 12.7% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q4 FY26₹619 Cr-13%
Q3 FY26₹545 Cr-19.5%
Q1 FY26₹549 Cr+13%

What management said about revenue

G

Q4 FY26 · Q1 FY27 to be low point for revenue and EBITDA

Revenue and EBITDA in Q1 FY27 expected to be weak due to revenue schedules skewed to H2, logistics cost inflation, and higher operating costs.

G

Q4 FY26 · Growth to return from H2 FY27

Recovery expected in second half of FY27, driven by order conversion, reloads, and improving utilization across the platform.

G

Q3 FY26 · FY26 revenue decline of early-to-mid double digits

Management revised FY26 revenue outlook to reflect an early-to-mid double-digit decline due to timing and product mix issues.

G

Q3 FY26 · FY27 expected to be a year of growth

Management expects FY27 to be a growth year driven by pipeline maturation and API recovery, but declined to quantify.

G

Q3 FY26 · Four phase 3 molecules expected to move to commercial supply in FY27

Four molecules across ADHD, antibiotic, and oncology are expected to enter commercial supply in FY27; two already have USFDA approval.

G

Q1 FY26 · FY26 revenue and margin guidance reiterated

Management reaffirmed FY26 guidance and long-term target of $1 billion revenue by 2030 with mid-30s EBITDA margins.

G

Q1 FY26 · Niche technology revenue share to reach mid-20s by FY26

Niche technology revenue share is expected to approach mid-20s by the end of FY26, up from above 20% in Q1.